Genenta Science SPA (FRA:K5F) Other Long-Term Liabilities: €-0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:K5F Genenta Science SPA FRA:K5F
37 GF Score
Price €0.68
! 4 Warning Signs
View Full Analysis

What is Genenta Science SPA Other Long-Term Liabilities?

Genenta Science SPA FRA:K5F -6.90% 37 Other Long-Term Liabilities is €-0.00 Mil as of Dec. 2025. GuruFocus rates FRA:K5F with a GF Score™ of 37/100. The stock has 4 warning signs investors should review.

Genenta Science SPA's other long-term liabilities for the quarter that ended in Dec. 2025 was €-0.00 Mil.

Genenta Science SPA's quarterly other long-term liabilities declined from Dec. 2024 (€0.00 Mil) to Jun. 2025 (€-0.00 Mil) and declined from Jun. 2025 (€-0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Genenta Science SPA's annual other long-term liabilities declined from Dec. 2023 (€0.01 Mil) to Dec. 2024 (€0.00 Mil) and declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€-0.00 Mil).

Genenta Science SPA Other Long-Term Liabilities Related Terms

Genenta Science SPA Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Genenta Science SPA's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genenta Science SPA Other Long-Term Liabilities Chart

Genenta Science SPA Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial -0.00 0.03 0.01 0.00 -0.00

Genenta Science SPA Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.00 -0.00 -0.00
FRA:K5F
37GF Score
Genenta Science SPA FRA:K5F
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genenta Science SPA Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of €-0.00 Mil mean?
Genenta Science SPA (FRA:K5F) has a Other Long-Term Liabilities of €-0.00 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genenta Science SPA and its competitors.
Is Genenta Science SPA's Other Long-Term Liabilities too high?
Genenta Science SPA's current Other Long-Term Liabilities is €-0.00 Mil. Overall, Genenta Science SPA has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Genenta Science SPA's Other Long-Term Liabilities compare to VRTX and REGN?
Genenta Science SPA's Other Long-Term Liabilities of €-0.00 Mil can be compared against companies in the Conglomerates industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Conglomerates company?
A good Other Long-Term Liabilities depends on the Conglomerates industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Genenta Science SPA and its competitors. Genenta Science SPA's current Other Long-Term Liabilities is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genenta Science SPA stock overvalued right now?
Genenta Science SPA (FRA:K5F) has a current Other Long-Term Liabilities of €-0.00 Mil. The current Other Long-Term Liabilities is €-0.00 Mil. Genenta Science SPA's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Genenta Science SPA (FRA:K5F), the current Other Long-Term Liabilities is €-0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genenta Science SPA Business Description

Other Exchanges GNTA:USA
Address Via dell’Annunciata No. 31, Milan, ITA, 20121
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
37GF Score

Get the complete analysis for FRA:K5F

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.68
Price